India Pharma Outlook Team | Monday, 01 December 2025
Sun Pharmaceutical Industries introduces its global innovative medication, Ilumya (Tildrakizumab), in India for moderate to severe plaque psoriasis. Ilumya, a new biologic therapy, has been broadly supported by dermatologists in the US and internationally for years as a safe and effective option for treating moderate to severe plaque psoriasis.
"Ilumya offers a safe and effective treatment options for patients who are struggling to manage their moderate-tosevere plaque psoriasis," said Kirti Ganorkar, Managing Director, Sun Pharma.
"We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years."
Also Read: Biocon Biologics Wins USFDA VAI Classification for Bengaluru Unit
Sun Pharma conducted a clinical trial in India involving 115 patients with moderate to severe plaque psoriasis. Notable enhancements were also seen in other efficacy endpoints, including the Dermatology Life Quality Index (DLQI) score A.
"Having been involved in the clinical development of Tildrakizumab in India, I am pleased to see its potential as an effective, safe, and long-lasting treatment for psoriasis.
In the Phase-3 trial, tildrakizumab demonstrated significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance." said Dr. B. S. Chandrashekar, Chief Dermatologist and Managing Director at Cutis Academy of Cutaneous Sciences, Bengaluru, India who was also an investigator in India Phase 3 trial. "These results showcase its benefits in improving the quality of life for psoriasis patients."
